Navigation Links
Nuvilex, Inc. Announces Positive Oraphyte(TM) Microplot Results
Date:9/14/2009

CHERRY HILL, N.J., Sept. 14 /PRNewswire-FirstCall/ -- Nuvilex, Inc. (OTC Bulletin Board: NVLX) announces today that results from the Company's ongoing sponsored research studies indicate that Oraphyte(TM) can control nematode infestation pre-plant and post-plant in several species of turfgrass. In the coming months Nuvilex intends to initiate trials on golf course greens in the Southeastern United States under conditions that are most optimal for turfgrass growth. These commercial studies will determine and validate Oraphyte's usage requirements and application specifications. Nuvilex plans to register Oraphyte with the Environmental Protection Agency (EPA) in two phases: Nuvilex will first register Oraphyte(TM) with the EPA as a pesticide for use on terrestrial, non-food crops, followed by pesticide registration for use on high-value crops (e.g., terrestrial food crop use) such as soybeans and sugar cane.

From 2007 to 2009, renowned nematologist Edward McGawley, Ph.D. of the Louisiana State University Agricultural Center (LSU AgCenter) has investigated the use of Oraphyte(TM) as an all-natural nematocide for turfgrass. Initial greenhouse and Phase 1 microplot experiments conducted in 2007 and 2008 demonstrated that Oraphyte(TM) could control populations of nematodes in turfgrass; however, early formulations appeared to be phytotoxic.

From May to August 2009, Phase 2 microplot experiments conducted at the LSU AgCenter included the application of a new and improved Oraphyte(TM) formula to six nematode genera that were added to the soil of Agrostis stolonifera (Penn G2 Bentgrass) and Cynodon (Bermudagrass). Both species of turfgrass were grown in microplots in a controlled environment. Each microplot contained approximately 15-35 kg of soil and approximately 1.7 ft2 of turfgrass. Preliminary results showed that the new and improved formulations caused a statistically significant reduction
'/>"/>

SOURCE Nuvilex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Nuvilex, Inc. Announces Reme-Flu(TM) as Trade Name for All-Natural Flu Remedy Formula
2. Nuvilex, Inc. Finalizes Joint Venture Agreement for the Development of Broad Spectrum All-Natural Flu Remedies
3. The KonLin Letter Issues Featured Stock Update on Nuvilex, Inc. in Its September 2009 Edition
4. Nuvilex, Inc. Sets Times and Locations for Upcoming Shareholder Meetings
5. Nuvilex, Inc. Announces Business Update Conference Call
6. Nuvilex, Inc. Announces Monthly Investor Conference Call
7. Nuvilex, Inc. Announces Investor Conference Call and Open House
8. Nuvilex, Inc.s Marketing Partner, CK41 to Launch purEffect(TM) in May
9. Nuvilex, Inc. Announces New Pricing for Cinnergen and Launch of dLife Advertising and Promotion Campaign
10. Nuvilex, Inc. Launches Spring Break Initiatives Designed to Raise Visibility Among Key Demographic Group
11. eFoodSafety.com, Inc. Changes Name to Nuvilex, Inc., Reflecting New Strategic Direction of Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Joan Lunden, award-winning American journalist, beloved ... upcoming 32nd Annual Miami Breast Cancer Conference ... LLC (PER®) , shares that “a fast-growing, virulent” cancer ... she had not followed up her clean mammogram with ...
(Date:1/22/2015)... La Jolla, Calif. (PRWEB) January 22, 2015 ... and Assemblymembers Susan Bonilla (D-Concord) and Kristin Olsen ... (CHI) for their leadership in advancing biotechnology, biomedical ... Mitchell, Bonilla and Olsen each received the “2014 ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 IsoComforter, Inc. has ... machine with patented IsoTube design to treat specific body parts ... the most progressive and easy to use patented cold therapy ... and sports related orthopedic and muscle injuries. IsoComforter has ...
(Date:1/22/2015)... Payday lending practices in four southern states ... distress to the states that permit them, according to ... on Race and Wealth. , While they generate hundreds ... at the same time substantially depress economic activity, according ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 As interest in ... health care gains momentum worldwide, Rev. Eric J. Hall ... Chaplaincy Network (HCCN), will be the keynote speaker on ... in Israel’s public health system. , The conference, “Hope and ...
Breaking Medicine News(10 mins):Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3
... has enough capacity for typical season; experts less sure about ... current swine flu outbreak is raising critical questions about the ... logistics of getting it to the people who need it. ... into this fall,s production of seasonal influenza vaccine, experts say. ...
... war, blast injuries have become the signature injuries. These ... cause damage to the visual system and the visual processing ... wrong with them." Gregory Goodrich, Ph.D., Veterans, Administration Research Psychologist, ... LAKE, N.Y., May 18 The journey home is a ...
... NewCardio,s platform technology delivers new levels of analysis ... May 18 NewCardio, Inc., (OTC Bulletin Board: ... announced that members of the Company,s medical and ... clinical data from analytical and clinical applications of ...
... Preliminary results from the first-of-its-kind Clinical Evaluation and ... at the Society of Gastroenterology Nurses and Associates, Inc. ... The study indicated that while there are written endoscope ... in the study, significant variation in manual reprocessing takes ...
... Data on frequency of resistance development and safety ... Microbiology and Infectious Diseases (ECCMID)SAN DIEGO, May 18 ... best-in-class drugs for the treatment of serious bacterial ... of torezolid (TR-701), a novel antibiotic that is ...
... from Alcon and Initial Payments from New Galderma ... Calif., May 18 NovaBay Pharmaceuticals, Inc. (NYSE ... company developing first-in-class anti-infective products for the treatment ... without causing resistance, reported today its financial results ...
Cached Medicine News:Health News:Adequate Supply of Swine Flu Vaccine Uncertain 2Health News:Adequate Supply of Swine Flu Vaccine Uncertain 3Health News:Becoming Aware of Veterans' Vision Needs 2Health News:NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference 2Health News:NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference 3Health News:NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference 4Health News:NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference 5Health News:First-of-its-Kind Study Released at the SGNA 36th Annual Conference Reveals Inconsistency in GI Endoscope Reprocessing 2Health News:First-of-its-Kind Study Released at the SGNA 36th Annual Conference Reveals Inconsistency in GI Endoscope Reprocessing 3Health News:First-of-its-Kind Study Released at the SGNA 36th Annual Conference Reveals Inconsistency in GI Endoscope Reprocessing 4Health News:Trius Presents New Data on Torezolid Antibiotic for Treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections 2Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 2Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 3Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 4Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 5Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 6Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 7Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 8Health News:NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financial Results 9
(Date:1/22/2015)... Jan. 22, 2015  ViewRay™, a privately held medical device ... exclusive distributor agreement with ITOCHU Corporation (Tokyo Stock Exchange ... for the treatment of cancer in Japan ... the world,s first and only MRI-guided radiation therapy system ...
(Date:1/22/2015)... Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty ... disease and overall health is pleased to provide you with ... outlook for 2015 from the CEO, Mr. Eugene Bortoluzzi ... like to take this opportunity to share with you the ...
(Date:1/22/2015)... Increasing sophistication among enterprise buyers of language services ... 2015, says Moravia CMO, Renato Beninatto ... market research firm Common Sense Advisory, 15 percent of ... and localization needs. "From a language industry perspective, this ...
Breaking Medicine Technology:ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7Moravia Sees Single-Sourcing as Key Localization Trend in 2015 2
... Dr. Michael Klein , director of the Food and Drug Administration (FDA) Controlled Substance ... abuse of prescription drugs.   , , , ... , , ... , , Learn more ...
... , July 28, 2010 , ... - Company Expands Market-leading Family of Neurovascular Stents , ... Boston Scientific Corporation (NYSE: BSX ... fourth-generation,intracranial aneurysm stent system designed for use in conjunction with,endovascular coiling to treat wide-necked ...
Cached Medicine Technology:FDA CONSUMER HEALTH INFORMATION - Combating Misuse and Abuse of Prescription Drugs: Q&A with Michael Klein, Ph.D. 2Boston Scientific Launches Neuroform EZ(TM) Stent System in U.S. and Europe 2Boston Scientific Launches Neuroform EZ(TM) Stent System in U.S. and Europe 3Boston Scientific Launches Neuroform EZ(TM) Stent System in U.S. and Europe 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: